Market Place
Sourcing Support
Elixirgen Gets Rare Pediatric Disease Tag For EXG-34217
25 Sep 2024 //
GLOBENEWSWIRE
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology
04 Mar 2024 //
GLOBENEWSWIRE
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003
16 Oct 2023 //
GLOBENEWSWIRE
Elixir Achieves 20 Consecutive Years of URAC PBM Accreditation
11 Oct 2023 //
BUSINESSWIRE
Elixirgen Therapeutics Enters MoU with Hitachi Global Life Solutions
26 Jan 2023 //
GLOBENEWSWIRE
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
04 Jan 2023 //
GLOBENEWSWIRE
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors
21 Dec 2022 //
GLOBENEWSWIRE
Elixirgen Presents New Data Demonstrating Ex Vivo Telomere Elongation EXG-34217
12 Dec 2022 //
GLOBENEWSWIRE
Elixirgen to Present New Data Showing Successful Ex Vivo Telomere Elongation
07 Nov 2022 //
GLOBENEWSWIRE
Elixirgen Tx Partners with Taisho Pharma on Aging-Associated Diseases
07 Mar 2022 //
PRNEWSWIRE
Elixirgen Announces Dosing of First and Second Participants in its COVID-19
25 May 2021 //
PRNEWSWIRE
Elixirgen Therapeutics to begin Phase I/II Clinical Trials of COVID-19 Vaccine
01 Sep 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.